Show simple item record

dc.creatorNtaios G., Lip G.Y.H.en
dc.date.accessioned2023-01-31T09:40:33Z
dc.date.available2023-01-31T09:40:33Z
dc.date.issued2016
dc.identifier10.1097/WCO.0000000000000283
dc.identifier.issn13507540
dc.identifier.urihttp://hdl.handle.net/11615/77277
dc.description.abstractPurpose of review A significant proportion of stroke patients is treated with anticoagulants for secondary stroke prevention. Often, in such patients, stroke physicians are required to make difficult clinical decisions when confronted with the dilemma to choose between the risk of thromboembolism and the risk of bleeding. This article focuses on three common anticoagulant-related situations, where the stroke physician needs to find the delicate balance between the two risks. Recent findings Three typical case vignettes are presented and the associated dilemmas are discussed: a patient with an anticoagulant-related intracranial hemorrhage: would you restart anticoagulation?, an anticoagulated patient with a previous stroke because of atrial fibrillation is scheduled for an elective polyp removal: how would you handle anticoagulation perioperatively?, and a patient presents with an ischemic stroke because of atrial fibrillation: how soon would you start anticoagulation for secondary stroke prevention? The article summarizes the related literature and discusses the pros and cons of each choice. Summary The available evidence is limited; we need to individualize our approach according to the specific characteristics of our patients, and share the decision process with our patients and their proxies, taking strongly into consideration their values and preferences. © 2016 Wolters Kluwer Health, Inc. All rights reserved.en
dc.language.isoenen
dc.sourceCurrent Opinion in Neurologyen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84952629698&doi=10.1097%2fWCO.0000000000000283&partnerID=40&md5=13b50b2e903735fab1c697717dff5d64
dc.subjectacenocoumarolen
dc.subjectapixabanen
dc.subjectdabigatranen
dc.subjectdalteparinen
dc.subjectedoxabanen
dc.subjectlow molecular weight heparinen
dc.subjectwarfarinen
dc.subjectanticoagulant agenten
dc.subjectanticoagulationen
dc.subjectarterial thromboembolismen
dc.subjectatrial fibrillationen
dc.subjectbleedingen
dc.subjectbrain hemorrhageen
dc.subjectbrain ischemiaen
dc.subjectcerebrovascular accidenten
dc.subjectcolon polypen
dc.subjecthumanen
dc.subjectintervention studyen
dc.subjectmedical decision makingen
dc.subjectperioperative perioden
dc.subjectrandomized controlled trial (topic)en
dc.subjectReviewen
dc.subjectrisk assessmenten
dc.subjectsecondary preventionen
dc.subjectthromboembolismen
dc.subjectatrial fibrillationen
dc.subjectcomplicationen
dc.subjectHemorrhageen
dc.subjectIntracranial Hemorrhagesen
dc.subjectrisk factoren
dc.subjectStrokeen
dc.subjectAnticoagulantsen
dc.subjectAtrial Fibrillationen
dc.subjectHemorrhageen
dc.subjectHumansen
dc.subjectIntracranial Hemorrhagesen
dc.subjectRisk Factorsen
dc.subjectStrokeen
dc.subjectLippincott Williams and Wilkinsen
dc.titleDifficult situations in anticoagulation after stroke: Between Scylla and Charybdisen
dc.typeotheren


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record